logo image
search icon
Peptide and Anticoagulant Drugs Market

Peptide And Anticoagulant Drugs Market Size, Share & Trends Analysis Report by Peptide Drug Type (Antibiotic, Hormonal, Antifungal, ACE Inhibitor), Anticoagulant Drug Type (Heparin, Edoxaban, Apixaban, Dabigatran, Rivaroxaban), Administration Route (Oral, Injectable), By Peptide Application (Neurological Disorders, Metabolic Disorders, Gastrointestinal Disorders, Diabetes, Cancer, Cardiovascular Disorder, Infectious Diseases), Region And Segment Forecasts, 2024-2031

Report ID : 1837 | Published : 2024-08-14 | Pages: 180 | Format: PDF/EXCEL

The Global Peptide And Anticoagulant Drugs Market Size is valued at 904.77 million in 2023 and is predicted to reach 1,413.01 million by the year 2031 at a 5.81% CAGR during the forecast period for 2024-2031.

Blood thinners are anticoagulants, which are chemical agents that decrease blood coagulation and the time it takes for blood to clot. Anticoagulants are a type of medicine that is used to treat thrombotic disorders. Oral anticoagulants are available in pill, tablet, and injectable forms. Heparin is an injectable anticoagulant that is routinely used in hospitals to keep blood clots from forming. DVT is treated with subcutaneous injections of LMWHs twice a day. 

Peptides, also known as amide bonds, are peptide bonds that connect long-chain amino acids. Peptides are a type of therapeutic material that is composed of small molecules and proteins. Peptide therapeutic properties are used to treat a wide range of illnesses. The rising healthcare expenditure, which aids in the improvement of infrastructure, is a factor impacting the growth rate of the peptide and anticoagulant medicines market. Furthermore, several government organizations intend to improve healthcare infrastructure by boosting financing, which would have an impact on market dynamics.

However, COVID-19 initially had a significant impact on market expansion. During the pandemic, several peptide-based vaccines and medication candidates were presented, which aided in the treatment of COVID-19 infections. As a result, the pandemic had a considerable impact on market growth. However, now that the epidemic has passed, the market will likely rise steadily over the projection period. 

Competitive Landscape:

Some of the Peptide and Anticoagulant Drugs Market players are:

  • Baxter
  • Celsus
  • Biofer
  • Hemmo Pharma
  • AmbioPharm
  • Wockhardt
  • Sun Pharmaceutical Industries
  • Bachem
  • Pfizer
  • Leo Pharma
  • Abbott Laboratories
  • Takeda
  • Aspen
  • Teva
  • Eli Lilly
  • Sanofi
  • Novo Nordisk
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co., Inc. 

Market Segmentation:

The peptide and anticoagulant drugs market is categorized on the basis of peptide drug type, anticoagulant drug type, administration route, and application. Based on peptide drug type, the market is segmented as an antibiotic, hormonal, antifungal, ace inhibitor, and others. The anticoagulant drug type segment include heparin, edoxaban, apixaban, dabigatran, rivaroxaban, and others. The market is segmented by administration route into oral, injectable, and others. The other applications segment include neurological disorders, metabolic disorders, gastrointestinal disorders, diabetes, cancer, cardiovascular disorder, infectious diseases, and others.

Based On Application, The Cancer Segment Is Accounted As A Major Contributor In The Peptide And Anticoagulant Drugs Market

The cancer category is expected to hold a major share in the global peptide and anticoagulant drugs market in 2024. Cancer patients are increasingly being treated with peptide and anticoagulant medicines. Historically, these medications have been used to prevent cardiovascular, diabetic, and neurological problems. Nonetheless, their ability to induce and strengthen antigen-specific immune responses has long been recognized as a potentially useful tool in cancer treatment.

The Antibiotic Segment Witnessed Growth At A Rapid Rate

The antibiotic segment is projected to grow at a rapid rate in the global peptide and anticoagulant drugs market. Antibiotic peptides are small peptides that play an important function in the innate immune system and are abundant in nature. Antibiotic peptides are tiny bioactive proteins that have piqued the interest of researchers as potential next-generation antibiotics.

In The Region, The North America Peptide And Anticoagulant Drugs Market Holds A Significant Revenue Share

The North America Peptide and Anticoagulant Drugs Market is expected to register the highest market share in terms of revenue in the near future. Due to the rising incidence of chronic diseases, particularly cancer, the region is experiencing rapid market expansion. Investment in pharmaceutical and biotechnology industries will fuel the North American peptide and anticoagulant medications market. Furthermore, the provision of cash for drug development processes draws a large number of worldwide companies. During the projection period, the Asia Pacific region is expected to grow profitably. Because of the rising burden of cancer and cardiovascular disorders in nations such as India, China, and Japan, the market is expanding at a rapid pace. 

Peptide And Anticoagulant Drugs Market Report Scope:

Report Attribute

Specifications

Market size value in 2023

USD 904.77 Mn

Revenue forecast in 2031

USD 1,413.01 Mn

Growth rate CAGR

CAGR of 5.81% from 2024 to 2031

Quantitative units

Representation of revenue in US$ Billion and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report coverage

The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends

Segments covered

Type, Material, Precursor And End Users

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Competitive Landscape

Baxter, Celsus, Biofer, Hemmo Pharma, AmbioPharm, Wockhardt, Sun Pharmaceutical Industries, Bachem, Pfizer, Leo Pharma, Abbott Laboratories, Takeda, Aspen, Teva, Eli Lilly, Sanofi, Novo Nordisk, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, and Merck & Co., Inc.

Customization scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and available payment methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Peptide and Anticoagulant Drugs Market Snapshot

Chapter 4. Global Peptide and Anticoagulant Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Peptide Drug Type Estimates & Trend Analysis
5.1. by Peptide Drug Type & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Peptide Drug Type:

5.2.1. Antibiotic
5.2.2. Hormonal
5.2.3. Antifungal
5.2.4. ACE Inhibitor
5.2.5. Others

Chapter 6. Market Segmentation 2: by Anticoagulant Drug Type Estimates & Trend Analysis
6.1. by Anticoagulant Drug Type & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Anticoagulant Drug Type:

6.2.1. Heparin
6.2.2. Edoxaban
6.2.3. Apixaban
6.2.4. Dabigatran
6.2.5. Rivaroxaban
6.2.6. Others

Chapter 7. Market Segmentation 3: by Administration Route Estimates & Trend Analysis
7.1. by Administration Route & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Administration Route:

7.2.1. Oral
7.2.2. Injectable
7.2.3. Others

Chapter 8. Market Segmentation 4: by Application Estimates & Trend Analysis
8.1. by Application & Market Share, 2023 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:

8.2.1. Neurological Disorders
8.2.2. Metabolic Disorders
8.2.3. Gastrointestinal Disorders
8.2.4. Diabetes
8.2.5. Cancer
8.2.6. Cardiovascular Disorder
8.2.7. Infectious Diseases
8.2.8. Others

Chapter 9. Peptide and Anticoagulant Drugs Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2023-2031
9.1.2. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2023-2031
9.1.3. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2023-2031
9.1.4. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
9.1.5. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

9.2. Europe

9.2.1. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2023-2031
9.2.2. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2023-2031
9.2.3. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2023-2031
9.2.4. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
9.2.5. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

9.3. Asia Pacific

9.3.1. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2023-2031
9.3.2. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2023-2031
9.3.3. Asia-Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2023-2031
9.3.4. Asia-Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
9.3.5. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

9.4. Latin America

9.4.1. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2023-2031
9.4.2. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2023-2031
9.4.3. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2023-2031
9.4.4. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
9.4.5. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

9.5. Middle East & Africa

9.5.1. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2023-2031
9.5.2. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2023-2031
9.5.3. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2023-2031
9.5.4. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
9.5.5. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles


10.2.1. Baxter
10.2.2. Celsus
10.2.3. Biofer
10.2.4. Hemmo Pharma
10.2.5. AmbioPharm
10.2.6. Wockhardt
10.2.7. Sun Pharmaceutical Industries
10.2.8. Bachem
10.2.9. Pfizer
10.2.10. Leo Pharma
10.2.11. Abbott Laboratories
10.2.12. Takeda
10.2.13. Aspen
10.2.14. Teva
10.2.15. Eli Lilly
10.2.16. Sanofi
10.2.17. Novo Nordisk
10.2.18. F. Hoffmann-La Roche Ltd.
10.2.19. Mylan N.V.
10.2.20. Teva Pharmaceutical Industries Ltd.
10.2.21. GlaxoSmithKline plc
10.2.22. Novartis AG
10.2.23. Merck & Co., Inc.
10.2.24. Other Prominent Players

Segmentation of Peptide and Anticoagulant Drugs Market-

Peptide and Anticoagulant Drugs Market By Peptide Drug Type -

  • Antibiotic
  • Hormonal
  • Antifungal
  • ACE Inhibitor
  • Others 

Peptide and Anticoagulant Drugs Market By Anticoagulant Drug Type-

  • Heparin
  • Edoxaban
  • Apixaban
  • Dabigatran
  • Rivaroxaban
  • Others

Peptide and Anticoagulant Drugs Market By Administration Route-

  • Oral
  • Injectable
  • Others

Peptide and Anticoagulant Drugs Market By Application-

  • Neurological Disorders
  • Metabolic Disorders
  • Gastrointestinal Disorders
  • Diabetes
  • Cancer
  • Cardiovascular Disorder
  • Infectious Diseases
  • Others

Peptide and Anticoagulant Drugs Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

 InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Peptide and Anticoagulant Drugs Market?

Peptide and Anticoagulant Drugs Market expected to grow at a 5.81% CAGR during the forecast period for 2024-2031.

Baxter, Celsus, Biofer, Hemmo Pharma, AmbioPharm, Wockhardt, Sun Pharmaceutical Industries, Bachem, Pfizer, Leo Pharma, Abbott Laboratories, Takeda

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach